Sensyne Health to Help Bayer Develop Cardiovascular Drugs

By Carlo Martuscelli

Sensyne Health PLC (SENS.LN) said Wednesday that it will work with Germany's Bayer AG (BAYN.XE) to help it identify new treatments for cardiovascular disease in a contract worth 5 million pounds ($6.1 million) over two years for the British clinical artificial intelligence company.

Under the terms of the collaboration agreement, Bayer will use Sensyne's technology platform to accelerate drug development. Trusts belonging to U.K.'s National Health Service, which have a stake in Sensyne and provide it with patient data, will be due a 4% share of revenues generated by the collaboration, the company said.

Shares of Sensyne at 0830 GMT were up 6.7% at 160 pence.

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

(END) Dow Jones Newswires

July 31, 2019 04:54 ET (08:54 GMT)

Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Mar 2024 to Apr 2024